Latent membrane protein 1 peptide–Major histocompatibility complex (LMP1-pMHC)

The Latent membrane protein 1 (LMP1) peptide–Major histocompatibility complex (pMHC) is a specialized therapeutic target consisting of a specific peptide fragment derived from the Epstein-Barr virus (EBV) LMP1 protein presented on the surface of host cells by MHC Class I molecules, most commonly HLA-A*02:01. LMP1 is a well-characterized viral oncogene that mimics CD40 signaling to promote cell survival and proliferation, playing a critical role in the pathogenesis of various EBV-associated cancers such as nasopharyngeal carcinoma and Hodgkin lymphoma. Because LMP1 is an intracellular protein, it is not accessible to traditional antibody therapies; however, its processed peptides presented on MHC allow for the development of TCR-like antibodies and CAR-T cells that can specifically recognize and eliminate infected cells. This target is particularly valuable because LMP1 expression is restricted to EBV-infected cells, potentially offering high specificity for treating viral-driven malignancies. Current therapeutic strategies focus on engineering T-cells or multispecific antibodies that can distinguish the LMP1-pMHC complex from similar self-peptide-MHC complexes to minimize off-target effects.

Other names

EBV LMP1-HLA complexLMP1 peptide-HLA-A*02:01 complexEpstein-Barr virus LMP1 epitope-MHCLMP1-MHC class I complex

Targeted cell lysis via T-cell receptor (TCR) engagement or chimeric antigen receptor (CAR) binding to the specific viral peptide presented on the cell surface MHC, leading to apoptosis of EBV-infected malignant cells.